Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.

European Journal of Gynaecological Oncology

Volumn 18, Issue 3, 1997, Pages 185-187

  Deltetto, F ^a,c   Durando, A ^a   Camanni, M ^b   Pesola, D ^a   Sberveglieri, M ^a   Arese, P ^a   Massobrio, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Ospedale SS Annunziata   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

Author keywords

Carboplatin; Chemotherapy; Etoposide; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030904793     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cocconi G., Bisagni G., Bacchi C. et al.: "Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research". J. Clin. Oncol., 1991, 9, 664.
2. Cox E., Burton G., Olsen G. et al.: "Cisplatin and etoposide: an effective treatment for refractory breast carcinoma". Am. J. Clin. Oncol., 1989, 12, 53.
3. Sledge G. W., Roth B. J.: "Cisplatin in the management of breast cancer". Sem. Oncol., 1989, 16, 110.
4. Muggia F. M.: "Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin". Semin. Oncol., 1988, 16 (Suppl. 5), 7.
5. Smith I, E., Harland S. J., Robinson B. A. et al.: "Carboplatin: a very active new cisplatin analogue in the treatment of small-cell lung cancer". Cancer Treat. Rep., 1985, 69, 43.
6. Rozencweig M.: "Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer". Bunn P. A., Canetta R., Philadelphia. Saunders, 1990, 175.
7. Sledge G. W. Jr.: "Cisplatin and platinum analogues in breast cancer". Semin. Oncol., 1992. 19 (Suppl. 2), 78.
8. Alberts D. S., Green S., Hanningan E. V. et al.: "Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages II and IV ovarian cancer. J. Clin. Oncol., 1992, 10, 706.
9. Swenertan K., Jeffrey J., Stuart G. et al.: "Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group". J. Clin. Oncol., 1992, 10, 718.
10. Radica P. A., Bunn P. A. Jr., Ihnde D. D., "Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer. non Hodgkin's lymphomas and other malignancies". Cancer Treat Rep., 1979, 63, 1231.
11. European Organization for Research and Treatment of Cancer, Cancer Study Group: "Epipodophyllotoxine in treatment of acute leukemias, hematosarcomas, and solid tumors". Br. Med. J . 1983, 3, 199.
12. Greco F. A.: "Etoposide: seeking the best dose and schedule". Semin. Oncol., 1992, 6 (Suppl. 14), 59.
13. Schell F. C., Yap H. Y., Hortobagy N. et al.: "Phase II of VP-16-213 (etoposide) in refractory metastatic breast carcinoma". Cancer Chemother. Pharmacol., 1982, 7, 223.
14. Fraschini G., Esparza L., Holmes F. et al : "High-dose etoposide (HD-E) in metastatic breast cancer". Breast Cancer Res. Treat., 1989, 14 (Abstr.), 142.
15. Calvert A. H., Newell D. R., Gumbrell L. A. et al.: "Carboplatin dosage: prospective evaluation of a simple formula based on renal function". Clin. Oncol., 1989, 7, 1748.
16. Miller A. B., Hoogstraten B., Staquet M. et al.: "Reporting results of cancer treatment". Cancer. 1981, 47, 207.
17. Crown J., Hakes T., Reichmann B. et al. "Phase II trial of carboplatin and etoposide in metastatic breast cancer". Cancer, 1993, 71, 1254.
18. Vinolas N., Daniels M., Estapé J. et al.: "Phase II of carboplatin and etoposide activity in pretreated breast cancer patients". Am. J. Clin. Oncol., 1992, 15, 160
19. Barker L. J., Jones S. E., Savin M. A. et al.: "Phase II evaluation of carboplatin and VP-16 for patients with metastatic breast cancer and only one prior chemotherapy regimen". Cancer, 1993, 72, 771.
20. Van der Gaast A., Bontembal M., Planting A. S. et al.: "Phase II of carboplatin and etoposide as a first-line regimen in patients with metastatic breast cancer". Ann. Oncol , 1990, 5 (9), 858.
21. Fields K. K., Elfenbein G. J., Perkins J. B. et al.: "Two novel high-dose treatment regimens for metastatic breast cancer ifosfamide, carboplatin plus etoposide and mitoxantrone plus tiothepa: outcomes and toxicities". Semin. Oncol , 1993, 20 (Suppl. 6), 59.
22. Ezzat A., Khalifa F., Berry J. et al.: "Phase II study of combination carboplatin and chronic oral VP 16 in pretreated metastatic breast cancer". Proc. Am. Soc. Clin. Onc., 1994, 13, 99.